The SCE Medical Oncology is unique among the Specialty Certificate Examinations because the knowledge base evolves faster than in any other medical specialty. New drug approvals, new NICE technology appraisals, new biomarker-driven treatment algorithms, and new immunotherapy indications appear continuously. A textbook that is current in January may be partially outdated by June. This means your preparation must be anchored to current guidelines and regularly updated resources rather than static textbooks alone.
The exam sits twice per year — February and September.
Topic weighting
The major tumour sites dominate. Breast cancer accounts for roughly 14 per cent — including ER/PR/HER2 classification, adjuvant chemotherapy and hormonal therapy, CDK4/6 inhibitors, BRCA-related management, and the evolving role of immunotherapy in triple-negative disease. Lung cancer accounts for another 14 per cent — NSCLC driver mutation testing (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK), PD-L1 expression and immunotherapy eligibility, staging-driven treatment decisions, and SCLC management. GI cancers (oesophageal, gastric, colorectal, pancreatic, HCC) account for 14 per cent collectively.
Urological cancers (prostate, renal cell, bladder, testicular) account for 8 per cent — prostate cancer management is particularly complex given the number of therapeutic options (enzalutamide, abiraterone, docetaxel, PARP inhibitors for BRCA-mutant disease, lutetium-177 PSMA). Gynaecological cancers account for 8 per cent. Melanoma accounts for 6 per cent.
Oncological emergencies account for 8 per cent — neutropenic sepsis (door-to-needle antibiotics within one hour), spinal cord compression (dexamethasone and urgent MRI within 24 hours), SVCO, tumour lysis syndrome (rasburicase for hyperuricaemia, aggressive hydration), and hypercalcaemia of malignancy (IV fluid resuscitation and zoledronic acid). These are high-yield because the management algorithms are precise and standardised.
Immunotherapy and targeted therapy — mechanism of action, biomarker selection, and irAE management — account for roughly 10 per cent and span all tumour sites.
The irAE challenge
Immune-related adverse events are tested in detail. You must know the common irAEs (colitis, hepatitis, pneumonitis, endocrinopathies, skin toxicity, neurological toxicity), their clinical presentation, grading (CTCAE grades 1 to 4), and the management algorithm for each grade — typically observation for grade 1, oral prednisolone for grade 2, high-dose IV methylprednisolone for grade 3, and permanent discontinuation of immunotherapy for grade 3 to 4. Specific irAEs have specific management — infliximab for steroid-refractory colitis, mycophenolate for steroid-refractory hepatitis, and hormone replacement for endocrinopathies (which are permanent, unlike most other irAEs).
Biomarker-driven treatment
The exam tests your ability to select treatment based on biomarker results. A patient with NSCLC and an EGFR exon 19 deletion receives osimertinib, not pembrolizumab — regardless of their PD-L1 expression. A patient with colorectal cancer and MSI-high status may be eligible for immunotherapy. A patient with breast cancer and BRCA1 mutation may benefit from a PARP inhibitor. You need to know which biomarkers determine which treatment for each tumour site.
Revision strategy
Three to four months. Spend the first six weeks on the three major tumour sites — breast, lung, and GI — which together account for over 40 per cent of the exam. Read the current NICE technology appraisals for each tumour site alongside question bank practice — the TAs define what you can actually prescribe in the UK, and the exam tests real-world prescribing decisions. Weeks seven to ten should cover urological, gynaecological, and melanoma, plus oncological emergencies. Weeks eleven to twelve should cover irAE management, remaining topics, and mock exams.
iatroX's SCE Medical Oncology bank contains over 1,500 questions covering all tumour sites, biomarker-driven treatment algorithms, NICE TA eligibility criteria, and irAE management. The adaptive algorithm ensures that less common tumour sites (sarcoma, CUP, CNS) receive proportional attention. All included at £29 per month or £99 per year.